The history of Viagra presents a complex picture for shareholders. While the initial launch generated massive gains, the lapse of its patent opened the door to cheaper competitors, dramatically diminishing sales. This presents a unique dilemma for pharmaceutical companies depending on comparable blockbuster products, suggesting that a blind partici

The legacy of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in sales , its exclusivity period created a wave of knock-off medications, significantly diminishing its dominance. While specific firms may seek to capitalize on similar conditions , the current